6-Sulfatoxy-Melatonin
The principal metabolite of Melatonin is 6-Sulfatoxymelatonin. The particular advantage of measuring 6-Sulfatoxymelatonin is the ability to assess pineal function by urine sampling, since urine contains only traces (approx. 1%) of non-metabolized Melatonin. The measurement of 6-Sulfatoxymelatonin in urine provides a non-invasive, integrated parameter by which circadian rhythms can be assessed over a period of time.

Melatonin is initially metabolized in the liver to 6-Hydroxymelatonin (aMT6S, M6S), then conjugated to sulphate and excreted into urine.
The production and excretion of 6-Sulfatoxy- melatonin follows an individual’s circadian rhythm, like Melatonin. Measurement of 6-Sulfatoxy- melatonin may be used as an index of pineal function.
For both, clinical and research purpose, the timing of nocturnal onset of 6-Sulfatoxymelatonin has been proposed as a reliable and robust marker of the circadian phase in order to diagnose disorders with an underlying circadian component e.g. advanced or delayed sleep phase syndrome, winter depression, shift work adaptation etc. Moreover, the position of the circadian phase is imperative for the implementation of therapies whose efficacy varies with the phase of the underlying endogenous circadian pacemaker such as the administration of bright light and/or exogenous Melatonin.
Product Information
| 6-Sulfatoxy-Melatonin | |
|---|---|
Method |
ELISA |
Time to results |
4 h |
Sample Type |
5 µl urine |
Standard Range |
0.8-40 ng/ml |
Sensitivity |
1.6 ng/ml |
Order Code |
EK-M6S 96 wells |
| CE | |
| DOWNLOADS | |
Instruction
|
|
English |
[PDF 0.3MB] |
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
| Your local distributor Order About us Job opportunities |
Search
News
The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked
The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E more
INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.
New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at more
Recent publications on BÜHLMANN calprotectin assays
Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an more
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |
